Figure 2.

PFS analysis of patients with nonmetastatic gastric cancer in relation to isolated CTCs and CTM at baseline. (A): Patients with the count of CTCs above 2.8 per mL versus those with count of CTCs under 2.8 per mL: median PFS not achieved for both (p = .103). (B): Patients with CTM presence had poor mean PFS in relation to those with CTM absence (18.7 months vs. 21.6 months, respectively; p = .258).

Abbreviations: CTCs, circulating tumor cells; CTM, circulating tumor microemboli; PFS, progression‐free survival.